The coagulation system

Coagulation initiates with tissue factor (TF), a cell membrane protein that binds activated factor VII (indicated by adding the letter ‘a’, i.e. factor VIIa). Although there is a small fraction of circulating factor VII in the activated state, it has little or no enzymatic activity until it is bound to TF. Most non-vascular cells express TF in a constitutive¹ fashion, whereas de novo TF synthesis can be induced in monocytes and damaged endothelial cells. Injury to the arterial or venous wall exposes extravascular TF-expressing cells to blood. Lipid-laden macrophages in the core of atherosclerotic plaques are particularly rich in TF, thereby explaining the propensity for thrombus formation at sites of plaque disruption. Once bound to TF, factor VIIa activates factor IX and factor X (to IXa and Xa, respectively), leading to thrombin generation and clot formation (Fig. 29.1).

Fig. 29.1 The blood coagulation network (see text).

The classical view of blood coagulation with separate ‘extrinsic’ and ‘intrinsic’ pathways initiated by either TF or contact with an anionic surface does not reflect physiological coagulation. It is now evident that coagulation does not occur as linear sequential enzyme activation pathways but rather by a network of simultaneous interactions, which undergo regulation and modulation during the thrombin generation process itself.

In the current model, blood coagulation starts with a transient release of tissue factor by damaged endothelium, resulting in the formation of sub-nanomolar amounts of thrombin via TF/VIIa-driven Xa formation (extrinsic-tenase). The initial thrombin activity is necessary to prime the system for a full thrombin explosion. Tissue factor pathway inhibitor (TFPI) rapidly shuts down this priming pathway and the full thrombin explosion is then dependent on factor IXa-driven Xa formation. Factor IXa-driven Xa formation (intrinsic-tenase) is amplified by the thrombin explosion itself, as thrombin forms a positive feedback loop by activating factor XIa (not shown in Fig. 29.1), which converts more IX to IXa.

Thrombin converts soluble fibrinogen into insoluble fibrin monomers, which spontaneously polymerise to form the fibrin mesh that is then stabilised and cross-linked by activated factor XIII (factor XIIIa), a thrombin-activated transglutaminase. Thrombin amplifies its own generation by:

Procoagulant drugs

Vitamin K

Vitamin K (‘Koagulation’ vitamin) is essential for normal coagulation. It occurs naturally in two forms. Vitamin K₁ (phylloquinone) is widely distributed in plants and K₂ includes vitamin synthesised in the alimentary tract by bacteria, e.g. Escherichia coli (menaquinones). Leafy green vegetables are a good source of vitamin K₁. Bile is required for the absorption of the natural forms of vitamin K, which are fat soluble. The storage pool of vitamin K is modest and can be exhausted in 1 week, although gut flora will maintain suboptimal production of vitamin K-dependent proteins. A synthetic analogue, menadione (K₃), is water soluble.

Vitamin K is necessary for the final stage in the synthesis of coagulation proteins in the liver: the procoagulant factors II (prothrombin), VII, IX and X, and anticoagulant regulatory proteins, proteins C and S. The vitamin allows γ-carboxylation of glutamic acid residues in their structure; this permits calcium to bind to the molecule, mediating the conformational change required for enzymatic activity, and binding to negatively charged phospholipid surfaces, e.g. platelets. Membrane binding is required for full enzymatic potential.

During γ-carboxylation of the proteins, the reduced and active form of vitamin KH₂ converts to an epoxide, an oxidation product. Subsequently vitamin K epoxide reductase converts oxidised vitamin K back to the active vitamin K, i.e. there exists an interconversion cycle between vitamin K epoxide and reduced vitamin K (Fig. 29.2).

Fig. 29.2 The vitamin K cycle.

When the vitamin is deficient or where drugs inhibit its action, the coagulation proteins produced are unable to associate with calcium in order to form the necessary three-dimensional configuration and associated membrane-binding properties that are required for full enzymatic activity. Their physiologically critical binding to membrane surfaces fails to occur, and this impairs the coagulation mechanism. These proteins are called ‘proteins induced in vitamin K absence’ or PIVKAs.

Oral vitamin K antagonists exert an anticoagulant effect by interrupting the vitamin K cycle. There are two classes of drugs: the coumarins, including warfarin and acenocoumarol, and the indanediones such as phenindione. The anticoagulant effect of oral vitamin K antagonists is expressed as the International Normalised Ratio (INR).

Vitamin K deficiency may arise from:

• dietary deficiency

• bile failing to enter the intestine, e.g. obstructive jaundice or biliary fistula

• malabsorption syndromes, e.g. coeliac disease, or after extensive small intestinal resection

• reduced alimentary tract flora, e.g. in newborn infants and rarely after broad-spectrum antibiotics.

The following preparations of vitamin K are available:

Phytomenadione

(Konakion), the naturally occurring fat-soluble vitamin K₁, acts within about 12 h and should reduce the anticoagulant effect of warfarin within 24–48 h when given orally in a dose of 5–10 mg. The intravenous formulation will begin to reverse a vitamin K-deficient coagulopathy within 6 h in a patient with normal liver function. It should be administered slowly to reduce the risk of an anaphylactoid reaction with facial flushing, sweating, fever, chest tightness, cyanosis and peripheral vascular collapse. Phytomenadione may also be given orally using either tablet formulations or the preparation for intravenous use. Oral administration will result in a slower and often incomplete correction of coagulopathy. Otherwise phytomenadione may be given intramuscularly, subcutaneously or orally. The preferred route depends on the degree of coagulopathy and urgency of correcting the haemorrhagic tendency. The intramuscular route should not be used if the INR is increased, as local intramuscular haemorrhage may be induced; subcutaneous absorption is variable and, despite the risk of allergic reaction, the intravenous route ensures rapid delivery.

Menadiol

sodium phosphate (vitamin K₃), the synthetic analogue of vitamin K, being water soluble, is preferred in intestinal malabsorption or in states in which bile flow is deficient. The main disadvantage is that it takes 24 h to act, but its effect lasts for several days. The dose is 5–40 mg daily, orally. Menadiol sodium phosphate in moderate doses causes haemolytic anaemia and, for this reason, neonates should not receive it, especially those that are deficient in glucose 6-phosphate dehydrogenase; their immature livers are unable to cope with the heavy bilirubin load and there is danger of kernicterus.

Fat-soluble analogues of vitamin K that are available in some countries include acetomenaphthone and menaphthone.

Vitamin K is used to treat the following:

• Haemorrhage or threatened bleeding due to the coumarin or indanedione anticoagulants. Phytomenadione is preferred for its more rapid action; dosage regimens vary according to the degree of urgency and the original indication for anticoagulation.

• Haemorrhagic disease of the newborn, which develops usually between 2 and 7 days, and late haemorrhagic disease that presents at 6–7 months. Prophylaxis is recommended during the period of vulnerability with vitamin K (phytomenadione, as Konakion) 1 mg by single i.m. injection at birth. Alternatively, give vitamin K by mouth as two doses of a colloidal (mixed micelle) preparation of phytomenadione in the first week. Breast-fed babies should receive a further 2 mg at 1 month of age. Formula-fed babies do not need this last supplement as the formula contains vitamin K. Fears that intramuscular vitamin K might cause childhood cancer have been dispelled.

• Intestinal malabsorption syndromes; menadiol sodium phosphate should be used as it is water soluble.

Coagulation factor concentrates

Bleeding due to deficiency of specific coagulation factors is treated by either elevating the deficient factor, e.g. treatment of mild factor VIII deficiency with desmopressin (see below), or replacement of the missing factor. Recombinant factor VIII and IX are now available in some countries for patients with congenital deficiency of these factors. For patients with rare coagulation factor deficiencies or multiple acquired deficiencies (liver disease, massive blood loss with dilutional coagulopathy or DIC), replacement therapy requires human-derived fresh frozen plasma (FFP) or factor concentrates containing factors II, VII, IX and X (Beriplex, Octaplex).

Solvent–detergent virally inactivated FFP (Octaplas) is currently given to selected patients in the UK, for example those with rare bleeding disorders and patients with thrombotic thrombocytopenic purpura who require repeated exposure to FFP. Methylene blue-treated single donor unit FFP is also available as a virally inactivated product.

Use of coagulation factor concentrates

Management of haemophilia A and haemophilia B (deficiency of factor VIII and IX, respectively) requires special expertise but the following points are notable:

• Superficial haemorrhage sometimes responds to local pressure.

• Minor bleeding can arrest with plasma factor concentrations of 0.25–0.30 units/mL, but severe bleeding requires at least 0.50 units/mL and surgical procedures or life-threatening haemorrhage require 0.75–1.00 units/mL by infusion of factor concentrate.

• In haemophilia A, factor VIII concentrate (t_½ 8–12 h) is used for bleeding that is more than minor. Repeat dosing is necessary to maintain haemostatic levels.

• Factor IX (t_½ 18–24 h) is used for bleeding that is more than minor in haemophilia B (Christmas disease).

• The speed of recovery of the affected joint or resolution of a haematoma determines the duration of therapy. After surgery, 7–14 days of replacement therapy is required to ensure adequate wound healing and to prevent secondary haemorrhage.

• Primary prophylaxis with factor concentrates two or three times weekly at doses sufficient to keep the factor above 0.01–0.02 units/mL reduces bleeding and hence the severity of chronic haemophilic arthropathy.

FEIBA is a human donor-derived factor concentrate for patients with inhibitory antibodies to factor VIII or IX. It contains a mixture of coagulation factors and produces thrombin generation even in the presence of inhibitors to factor VIII or IX.

Recombinant factor VIIa (NovoSeven) is effective for patients with inhibitory antibodies to factor VIII or IX or deficiency of factor VII. A pure synthetic activated coagulation factor, it generates thrombin even in the presence of inhibitors to factor VIII or IX. Owing to its short duration of action, three doses (90 μg/kg) are usually necessary at 2-h intervals. Alternatively a single large dose can be used (270 μg/kg).

Desmopressin (DDAVP)

Desmopressin is a vasopressin analogue that increases the plasma concentrations of factor VIII and von Willebrand factor, and directly activates platelets. DDAVP is usually given subcutaneously or intravenously, but unwanted effects (headache, flushing and tachycardia) are less severe after subcutaneous use. A concentrated form is available for intranasal use.

DDAVP is useful for treating patients with mild haemophilia A and von Willebrand’s disease, especially for short-term therapy. For dental extraction, a single injection of 0.3 micrograms/kg 1–2 h before surgery, combined with the oral antifibrinolytic drug, tranexamic acid, for 5–7 days after the procedure (see Antifibrinolytic drugs, p. 492), will produce normal haemostasis and prevent secondary haemorrhage.

Patients with Type 3 (severe) or some forms of Type 2 von Willebrand’s disease (VWD) and some with Type 1 with severe haemorrhage, or patients who require major surgery, need replacement therapy with human-derived intermediate-purity factor VIII concentrate known to contain high molecular weight von Willebrand factor (vWF) multimers. The larger multimers are required for normal haemostatic function. Cryoprecipitate that is rich in factor VIII and vWF is not virally inactivated and should not be used for patients with VWD or mild to moderate factor VIII deficiency.

DDAVP shortens the bleeding time in patients with renal or liver failure.

Adverse effects

Water retention and hyponatraemia may complicate therapy and very young children (< 1 year) should not receive DDAVP. Fluid intake should not exceed 1 L in the 8 h following treatment and with repeated doses the plasma sodium should be monitored. Tachyphylaxis (progressively diminishing response to the same dose) can occur.

Other agents

Adrenaline/epinephrine

is effective as a topical agent for epistaxis, applied in ribbon gauze that is packed into the nostril, haemorrhage being arrested by local vasoconstriction.

Fibrin glue

consists of fibrinogen and thrombin contained in two syringes, the tips of which form a common port that allows delivery of the two components to a bleeding point where fibrinogen converts to fibrin at a rate determined by the concentration of thrombin. Fibrin glue can be used to secure surgical haemostasis, e.g. on a large raw surface, and to prevent external oozing of blood in patients with haemophilia (see also above).

Sclerosing agents

produce inflammation and thrombosis in veins to induce permanent obliteration, e.g. ethanolamine oleate injection, sodium tetradecyl sulphate (given intravenously for varicose veins) and oily phenol injection (given submucosally for haemorrhoids). Local reactions and tissue necrosis may occur.